FDA seeking public input for clinical trials of psychedelic drug
Ibogaine comes from the bark and root of the Tabernanthe iboga shrub, which is crushed and consumed as a powder or given as an extract. The US is moving toward clinical trials of the substance, which is viewed as a potential treatment for opioid addiction and other conditions. Credit:
Nigel Dodds/Alamy
The US Food and Drug Administration on Monday issued a request for information for designing clinical trials for ibogaine, a psychoactive drug that proponents say holds promise for treating conditions like opioid addiction and post-traumatic stress disorder.
The agency is specifically seeking advice on patient selection, dosing, safety, and ethical considerations, such as how to gather informed consent from trial participants, who may experience effects like hallucinations. The public can submit comments until Nov. 20.
